Infinitopes, an Oxford University spinout and BioEscalator resident supported by Cancer Research UK (CRUK), will present the following posters:
Poster Title: A randomised, placebo-controlled, multi-centre Phase I/IIa study evaluating the safety and clinical activity of a novel viral vector cancer vaccine (ITOP1) in patients with resectable oesophageal adenocarcinoma (VISTA study)
Poster Title: Vaccination with a single dose of a novel delivery platform confers durable >8 month immune responses, with lasting protection against tumour and metastases in preclinical models
Poster Title: Precision ImmunomicsTM: Identification of hundreds of novel cancer antigens using a sensitive immunopeptidomics-led platform
Infinitopes announced its oversubscribed £12.8 million seed financing in April 2024 to advance its AI/ML Precision ImmunomicsTM antigen discovery platform. The company is positioned to launch its lead vaccine candidate ITOP1 in a double-blind, randomised, placebo-controlled phase I/IIa clinical trial at four UK NHS university cancer centres to treat patients with oesophageal cancer (OC).
Jonathan Kwok, Chief Executive Officer & Co-Founder at Infinitopes, said:
Using our integrated ‘right targets, right vectors, right patients, right time’ approach, we aim to address the unmet clinical need for durably effective, accessible therapies to save lives by preventing or significantly delaying disease recurrence for cancer patients.
For more information about Infinitopes, visit https://www.infinitopes.com/